FIXX - Homology Medicines Inc Stock Price, Fair Value and News

$29.09-2.32 (-7.39%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FIXX Price Action

Last 7 days

-27.3%

Last 30 days

-33.6%

Last 90 days

-10.7%

Trailing 12 Months

219.9%

FIXX RSI Chart

FIXX Valuation

Market Cap

354.3M

Price/Earnings (Trailing)

-22.05

Price/Sales (Trailing)

76.32

EV/EBITDA

-12.35

Price/Free Cashflow

-2.2K

FIXX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FIXX Fundamentals

FIXX Revenue

Revenue (TTM)

7.6M

FIXX Earnings

Earnings (TTM)

-16.1M

Earnings Growth (Yr)

46.61%

Earnings Growth (Qtr)

-3.63%

FIXX Profitability

EBT Margin

-287.39%

Return on Equity

-87.82%

Return on Assets

-15.37%

Free Cashflow Yield

-0.04%

FIXX Investor Care

Shares Dilution (1Y)

278.45%

Diluted EPS (TTM)

21.9

FIXX Alerts

Temasek Holdings (Private) Ltd reported owning 2.6% of FIXX [2024-10-25]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	8.8M	11.2M	11.8M	7.6M
2022	27.1M	20.3M	13.5M	6.7M
2021	31.4M	33.0M	34.1M	34.0M
2020	1.9M	2.2M	2.4M	2.7M
2019	4.5M	4.8M	4.9M	1.7M
2018	0	0	4.3M	4.3M
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Homology Medicines Inc

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

CEO	Dr. Albert Seymour Ph.D.
WEBSITE	homologymedicines.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	92

Homology Medicines Inc Frequently Asked Questions

What is the ticker symbol for Homology Medicines Inc? What does FIXX stand for in stocks?

FIXX is the stock ticker symbol of Homology Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Homology Medicines Inc (FIXX)?

As of Mon Nov 18 2024, market cap of Homology Medicines Inc is 354.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FIXX stock?

You can check FIXX's fair value in chart for subscribers.

Is Homology Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether FIXX is over valued or under valued. Whether Homology Medicines Inc is cheap or expensive depends on the assumptions which impact Homology Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FIXX.

What is Homology Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 18 2024, FIXX's PE ratio (Price to Earnings) is -22.05 and Price to Sales (PS) ratio is 76.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FIXX PE ratio will change depending on the future growth rate expectations of investors.